Want to see AU:CBL full AI Analyst Report?
Top Page
Control Bionics Ltd.
(Sydney:CBL)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.07
▲(23.33% Upside)
Action:Reiterated
Date:06/11/26
The score is held down primarily by weak financial quality—ongoing losses and negative/declining cash flow despite revenue growth. Technicals are supportive with price strength above moving averages, but momentum indicators are extremely stretched, adding pullback risk. Valuation is also constrained by negative earnings and no dividend yield data.
Positive Factors
Top-line Growth
Sustained revenue growth of ~16% indicates rising product adoption and expanding addressable market for assistive technologies. Durable top-line expansion helps absorb fixed costs, supports longer-term scaling of operations, and underpins potential path to profitability if margins improve.
Negative Factors
Cash Flow Weakness
Persistent negative operating cash flow undermines liquidity and forces reliance on external financing or equity raises. Over a multi-quarter horizon this can constrain product investment, slow commercialization, and increase dilution or refinancing risk if cash generation isn't restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Top-line Growth
Sustained revenue growth of ~16% indicates rising product adoption and expanding addressable market for assistive technologies. Durable top-line expansion helps absorb fixed costs, supports longer-term scaling of operations, and underpins potential path to profitability if margins improve.
Read all positive factors
Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$30.49M
Dividend YieldN/A
Average Volume (3M)173.99K
Price to Earnings (P/E)―
Beta (1Y)-0.11
Revenue Growth14.88%
EPS Growth35.94%
CountryAU
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.02
Shares Outstanding411,961,880
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$14.30M
Control Bionics Ltd. Business Overview & Revenue Model
Company Description
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the Ne...
How the Company Makes Money
null...
Control Bionics Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.07M | 6.14M | 5.35M | 5.64M | 4.50M | 4.09M |
| Gross Profit | 326.42K | 4.11M | 3.90M | 3.71M | -2.91M | 2.50M |
| EBITDA | -5.50M | -5.14M | -5.01M | -5.14M | -5.92M | -3.40M |
| Net Income | -6.50M | -6.11M | -5.91M | -5.63M | -6.11M | -3.55M |
Balance Sheet | ||||||
| Total Assets | 9.93M | 8.23M | 9.03M | 8.70M | 13.44M | 18.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.06M | 672.66K | 980.76K | 935.50K | 5.21M | 12.33M |
| Total Debt | 258.10K | 435.40K | 961.74K | 128.50K | 284.82K | 14.87K |
| Total Liabilities | 2.20M | 2.72M | 2.76M | 1.58M | 1.51M | 1.19M |
| Stockholders Equity | 7.73M | 5.51M | 6.27M | 7.15M | 11.92M | 17.16M |
Cash Flow | ||||||
| Free Cash Flow | -4.46M | -4.57M | -5.38M | -4.98M | -5.75M | -4.04M |
| Operating Cash Flow | -4.13M | -4.27M | -4.91M | -4.53M | -5.60M | -3.99M |
| Investing Cash Flow | -704.37K | -744.78K | -473.09K | -457.54K | -147.74K | -53.40K |
| Financing Cash Flow | 6.93M | 4.63M | 5.43M | 706.43K | -87.33K | 14.92M |
Control Bionics Ltd. Technical Analysis
Neutral
0.06
Price Trends
0.07
Positive
0.06
Positive
0.06
Positive
Market Momentum
<0.01
Positive
35.66
Neutral
3.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Neutral. The current price of 0.06 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.07, and above the 200-day MA of 0.06, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 35.66 is Neutral, neither overbought nor oversold. The STOCH value of 3.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CBL.
Control Bionics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$30.49M | -3.59 | -98.14% | ― | 14.88% | 35.94% | |
44 Neutral | AU$42.87M | -8.83 | -547.06% | ― | -19.47% | 62.28% | |
44 Neutral | AU$7.14M | >-0.01 | 459.94% | ― | 15.99% | 32.95% | |
43 Neutral | AU$3.12M | -0.67 | -358.43% | ― | -52.22% | 44.79% | |
41 Neutral | AU$15.34M | -3.04 | -58.40% | ― | -7.00% | 44.55% |
* Healthcare Sector Average
AU:CBL
Control Bionics Ltd.
0.07
0.04
138.71%
AU:UCM
Uscom Limited
0.01
>-0.01
-25.00%
AU:HMD
HeraMED Ltd.
0.04
0.02
184.62%
AU:AT1
Atomo Diagnostics Ltd.
0.02
<0.01
70.00%
AU:ADR
Adherium Ltd.
0.13
-0.06
-31.58%
Control Bionics Ltd. Corporate Events
Control Bionics Issues Nearly 30 Million New Shares Under Regulatory Exemption
Jul 1, 2026
Control Bionics Limited has issued 29,935,788 fully paid ordinary shares as of 1 July 2026, expanding its share capital base without providing a disclosure document under Part 6D.2 of the Corporations Act. The company states it is compliant with i...
Control Bionics Lists Nearly 30 Million New Shares on ASX
Jul 1, 2026
Control Bionics Limited has applied for quotation on the ASX of 29,935,788 ordinary fully paid shares under the code CBL, with an issue date of July 1, 2026. The new quotation relates to securities issued as part of previously announced transactio...
Control Bionics Showcases Neural-Signal Platform at LSI Asia Medtech Summit
Jun 30, 2026
Control Bionics Limited, a neurotechnology firm listed on the ASX, develops and commercialises non-invasive surface electromyography-based neural-signal platforms that translate muscle-generated electrical activity into actionable data. Its scalab...
Control Bionics Plans Major Share Placement to Fund Growth
Jun 25, 2026
Control Bionics Ltd. has lodged a notice with the ASX for a proposed placement of up to 96.7 million new fully paid ordinary shares, with an expected issue date of 12 August 2026. The capital raising is set to significantly increase the company...
Control Bionics Launches Securities Purchase Plan to Raise Capital
Jun 25, 2026
Control Bionics Limited has announced a new share offer under a securities purchase plan, proposing to issue up to 6,666,666 ordinary fully paid shares to eligible shareholders. The offer is based on a record date of 24 June 2026, with application...
Control Bionics Plans 29.6 Million-Share Placement to Fund Growth
Jun 25, 2026
Control Bionics Ltd. has notified the ASX of a proposed placement of up to 29.6 million new fully paid ordinary shares, with the issue expected to occur on 1 July 2026. The capital raising, conducted via a share placement, is set to materially exp...
Control Bionics Raises Up to A$10m to Accelerate Neurotechnology Expansion
Jun 25, 2026
Control Bionics has secured firm commitments to raise A$9.5 million via a two‑tranche share placement at A$0.075 per share, a discount to recent trading levels, with support from existing and new institutional, sophisticated and professional...
Control Bionics Halts Trading Ahead of Material Capital Raising
Jun 24, 2026
Control Bionics Limited has requested an immediate trading halt of its securities on the ASX as it prepares to announce details of a material capital raising. The halt will remain in place until the earlier of the company’s announcement on t...
Control Bionics Issues Cautionary Notice on Neurotechnology Presentation
May 4, 2026
Control Bionics has released a presentation outlining general information about its business and neurotechnology offerings, while stressing that the material is high-level and not tailored to any specific commercial or financial circumstances. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.